



CLAIMS ON APPEAL

1-38. (Canceled)

39. A method for inhibiting prostate tumor growth in a mammalian host determined to have a metastatic prostate tumor and comprising prostate tumor cells expressing native NKG2D, the method comprising steps:

administering to the mammalian host a composition comprising an NKG2D-binding agent, wherein the NKG2D-binding agent is multivalent and comprises a plurality of non-covalently linked NKG2D-binding moieties of natural NKG2D ligands, wherein the moieties are restricted to a common presenting surface, wherein the common presenting surface is of a host-compatible cell transduced to express the binding moieties, wherein the natural NKG2D ligands are selected from the group consisting of MICA, MICB and ULBP, wherein the administering step is effective to inhibit growth of the tumor; and

detecting a resultant inhibition of growth of the tumor by evaluating growth of the tumor.

40-44. (Canceled)

<sup>2</sup>  
~~45.~~ The method of claim <sup>1</sup>~~39~~, wherein the host-compatible cell is derived from the tumor.

46-50. (Canceled)

51. A method for inhibiting primary mammary tumor growth in a mammalian host determined to have a primary mammary tumor and comprising mammary tumor cells expressing native NKG2D, the method comprising steps:

administering to the mammalian host a composition comprising an NKG2D-binding agent, wherein the NKG2D-binding agent is multivalent and comprises a plurality of non-covalently linked NKG2D-binding moieties of natural NKG2D ligands, wherein the moieties are restricted to a common presenting surface, wherein the common presenting surface is of a host-compatible cell transduced to express the binding moieties, wherein the natural NKG2D ligands

are selected from the group consisting of MICA, MICB and ULBP, wherein the administering step is effective to inhibit growth of the tumor; and  
detecting a resultant inhibition of growth of the tumor by evaluating growth of the tumor.

52. (Canceled)

<sup>4</sup>  
~~53.~~ The method of claim <sup>3</sup>~~51~~, wherein the host-compatible cell is derived from the tumor.

54. (Canceled)